ATRC News and Press, AtriCure Inc. From 08/27/19

Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global Healthcare Conference in New York C...

Now China claims US broke the negotiation agreement The market futures plunge after China threatens retaliation. Then China backtracks, and the market goes back up. China claims the US broke the agreement; we say China did. Am I the only one who is bored with the whole nonsense? All I can ...

Quick Take AtriCure ( ATRC ) announced it has agreed to acquire SentreHEART for $40 million plus additional contingent consideration of up to $260 million. SentreHEART is developing percutaneous left atrial appendage management solutions. With the deal, ATRC is gaining promising techno...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial a...

Investors appear to lack enthusiasm for AtriCure's ( ATRC -8.1% ) planned takeover of SentreHEART, the developer of a suture delivery device called LARIAT for left atrial appendage closure. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on t...

AtriCure (NASDAQ: ATRC ) has agreed to acquire privately held SentreHEART , a developer of percutaneous left atrial appendage management solutions. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...

Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atri...

The following slide deck was published by AtriCure, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...